ATLANTA, Sept. 1, 2020 /PRNewswire/ — Micron Biomedical, Inc. (Micron) just lately acquired a second tranche of funding ($2.6M) to proceed medical improvement of its microneedle-based know-how for measles and rubella vaccination from the Invoice & Melinda Gates Basis. This work leverages Micron’s know-how, which has already been efficiently evaluated in medical research together with a Part 1 trial of an FDA-approved seasonal influenza vaccine.
Micron’s applicator-free know-how is well-suited for the administration of vaccines and, specifically, for measles-rubella vaccination in low- and middle-income international locations as it’s designed to supply the next advantages and benefits over vaccination by commonplace hypodermic needle and syringe: sturdy immune response as a result of vaccine supply to the pores and skin, wealthy in immune system cells; administration by minimally-trained personnel; era of sharps-free waste; small footprint; no want for reconstitution prior to make use of; and potential to cut back or remove the necessity for chilly chain transportation and storage. “These advantages, together with the truth that the know-how is painless, goal to extend recipients’ and vaccinators’ compliance and acceptability,” mentioned Steven Damon, Micron’s CEO.
Based on an April 7,2020 Nature article, “Why measles deaths are surging — and coronavirus might make it worse,” there was a 58% enhance in measles instances and associated deaths from 2016 to 2018, estimated to be 10 million worldwide with 140,000 deaths in 2018. Consultants say the surge in measles instances and deaths worldwide is a results of a number of elements together with the dearth of entry to vaccinations in poor international locations, the refusal to vaccinate youngsters in richer international locations and the suspension of measle vaccinations to concentrate on pandemics like COVID-19.
“We’re dedicated to using our know-how and expertise in the direction of the aim of reaching elimination of measles and rubella, which may be devastating to youngsters and households, particularly in poorer international locations. We’re honored to be supported by the Gates Basis as we proceed our work collectively,” mentioned Steven Damon.
Concerning Micron Biomedical:
Micron is an Atlanta-based firm whose microneedle know-how was initially developed in Mark Prausnitz’s lab at Georgia Tech. Co-founded by Mark Prausnitz, PhD, Devin McAllister, PhD and Sebastien Henry, MS, MBA, Micron has additional developed the know-how and emerged as a pacesetter within the subject of dissolvable microneedle-based, vaccine and drug supply know-how. Micron’s companions and funders embrace the Facilities for Illness Management and Prevention (CDC), the Invoice & Melinda Gates Basis, UNICEF, Georgia Analysis Alliance, and several other non-public and public undisclosed pharmaceutical corporations.
For extra data go to: www.micronbiomedical.com
For IR / Media / Partnering:
SOURCE Micron Biomedical, Inc.